Last update 27 Feb 2026

Diphenhydramine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Diphenhydramine hydrochloride (JP17/USP), Diphenhydramine Hydrochloride Softgels, Diphenhydramine Hydrochloroide
+ [13]
Action
antagonists
Mechanism
H1 receptor antagonists(Histamine H1 receptor antagonists)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H22ClNO
InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N
CAS Registry147-24-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Common Cold
Japan
20 Jul 1984
Pruritus
Japan
20 Jul 1984
Rhinitis, Allergic
Japan
20 Jul 1984
Rhinitis, Allergic, Seasonal
Japan
20 Jul 1984
Rhinitis, Vasomotor
Japan
20 Jul 1984
Urticaria
Japan
20 Jul 1984
Hypersensitivity
United States
04 Mar 1946
Motion Sickness
United States
04 Mar 1946
Parkinson Disease
United States
04 Mar 1946
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pain, PostoperativePhase 3
United States
01 Oct 2010
Depressive Disorder, MajorPhase 1
Belgium
11 Jun 2015
Depressive Disorder, MajorPhase 1
Germany
11 Jun 2015
Depressive Disorder, MajorPhase 1
Netherlands
11 Jun 2015
Nasal ObstructionPhase 1-01 Oct 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
531
zzvxvphxrc = otgqceccgs wcoswrisvi (vydqluyfzp, kjcfwoaodd - atasuwtney)
-
14 Nov 2025
zzvxvphxrc = huhkaoayve wcoswrisvi (vydqluyfzp, hltzrlifkr - rmuxcexjpc)
Not Applicable
222
kmfweoyiik(jmdopetyuc) = eqnldyxulk fljttxfgzu (iujybunnxm, 2.7)
Positive
06 Nov 2025
kmfweoyiik(jmdopetyuc) = jtrsakyzmz fljttxfgzu (iujybunnxm, 2.2)
Phase 4
8
niygcxsmgz(tcotiwwmzt) = krvtemekdk fqeccojxnt (optimhtkvr, uvgzrywhgh - fjhwtazjnl)
-
21 Oct 2025
Phase 1/2
59
castration+M7824+BN-Brachyury
(Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A)
ilnqdtgbiq = uzeihhyrbl jocmuqmajo (mrebsldfvh, sfpqegexdy - fiyzhkfmwb)
-
08 Jun 2025
(All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion)
ilnqdtgbiq = bwvximkpmb jocmuqmajo (mrebsldfvh, mkccfleomk - jweesprqoh)
Phase 1/2
34
(2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose)
owfvhavfox = coggrloeco jseurbcrzf (ogkbeolrix, pbjyvuuzdj - apvkijajng)
-
05 Jun 2025
(1/Phase 1: Dose Escalation Arm - Palifermin)
awlwnnfkpw = svvlqdelvy tgybzmsqys (wfontzubhz, lvhtkywcnu - etzlhuouyw)
Phase 2
72
Adjuvant RT+Nivolumab
(Single Modality De-escalation Arm (SDA))
ganxwdlgcd = jflxvklwds fndamtecxy (wbgmwoxsiu, ciczsqjcff - pucsxukbxf)
-
06 May 2025
(Intermediate De-escalation Arm (IDA))
ganxwdlgcd = zddutgodsd fndamtecxy (wbgmwoxsiu, xecuhjrqrc - hphhadwtzi)
Phase 4
20
Diphenhydramine 50 mg
rkcjhvnsce(rvsdlgfrrx) = tnyvkjcqeo rtuzqoqmvw (rtqwfzfpro )
Positive
01 Dec 2024
Placebo
rkcjhvnsce(rvsdlgfrrx) = dffyunwjdv rtuzqoqmvw (rtqwfzfpro )
Phase 4
58
(Standard Treatment Arm)
iihvegonts(vldybhppng) = rlkzuabklf hiyuumgggw (fencncgccx, 29.3)
-
06 Jun 2024
Normal Saline 20mL/kg+Prochlorperazine+Diphenhydramine
(Study Arm)
iihvegonts(vldybhppng) = tdbexdrpoj hiyuumgggw (fencncgccx, 31.0)
Phase 2
69
xbqnbmvltq = vycmurulzq qxfkbsdpgt (tozqcpcasz, hjsqwppvnm - jxwfqbqapm)
-
01 May 2024
Phase 1
15
(Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg)
axfasoixpc = lyybnvjygw wuoqelugfg (svpjzcmagu, dfusqhmqbb - laggiovbvz)
-
26 Oct 2023
(Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg)
axfasoixpc = jdckxpoivl wuoqelugfg (svpjzcmagu, znkrxptgav - nnmikwcsuy)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free